139 results about "Prognosis biomarker" patented technology

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

The invention discloses a screening method of colorectal cancer treatment prognosis biomarkers. The screening method includes the following steps of: (1) making a primary search strategy for screening the biomarkers; (2) making a literature adopting and exclusion criterion; (3) analyzing data and primarily screening the biomarkers; (4) making evident grades; (5) making a high quality evident evaluation criterion; (6) performing grading retrieval and quality evaluation on biomarker clinic evident; (7) performing data analyzing and statistics on the biomarker clinic evident; (8) screening the prognosis biomarkers. The invention further provides the colorectal cancer treatment prognosis biomarkers obtained through screening according to the screening method, and the prognosis biomarkers include KRAS, TYMS, TYMS, EGFR, UGT1A1*28, DPYD, PIK3CA, ERCC1, PTEN, VEGFR, BRAF, GST P1, XRCC1, MTHFR, MSI and the like.

The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.

The invention discloses a method for establishing a pancreatic cancer miRNA prognosis model and screening a targeted gene. The model comprises hsa-mir-424, hsa-mir-126, hsa-mir-3613 and hsa-mir-4772,nine key genes are identified, and the nine key genes comprise MMP14, ITGA2, THBS2, COL1A1, COL3A1, COL11A1, COL6A3, COL12A1 and COL5A2. According to the method for establishing the pancreatic cancermiRNA prognosis model, by means of TCGA and GEO databases, data is subjected to multi-step analysis through a plurality of R language installation packages and combines with clinical information, a Cox proportional risk regression model is established to search for prognosis biomarkers, the targeted gene of miRNA is predicted, the key genes related to pancreatic cancer are found out by utilizing Cytoscape, and related molecular functions and action mechanisms of the key genes are predicted through KEGG and GO analysis so as to search for new treatment targets and prognosis markers of pancreatic cancer patients.

The invention discloses gene sets and a scoring model for evaluating a tumor microenvironment, and application of the gene sets, and belongs to the field of biological information. It is proved for the first time that the gastric cancer has remarkable tumor microenvironment typing, and prognosis difference of gastric cancer patients with different typing is remarkable. According to a constructionmethod of the multi-gene scoring model for evaluating the gastric cancer tumor microenvironment, 44 gene sets capable of representing different microenvironment types are screened out, and the prediction efficiency of the tumor microenvironment multi-gene scoring model corresponding to the gene sets is remarkably better than that of other existing models; and the model is not only a prognostic marker of a gastric cancer patient, but also has a quite remarkable prediction effect in pan-cancer. The model provided by the invention not only can be used as a good prognosis biomarker, but also can be used for predicting checkpoint inhibitor immunotherapy response of various tumors by effectively evaluating the tumor microenvironment, and has important significance and clinical application valuefor better screening immunotherapy benefiting people.

The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein.

The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. Favorable response to anti-VEGF therapy is indicated by high expression levels of certain biomarkers or by low expression levels of certain biomarkers. An exemplary predictive biomarker is VEGF-A. Also disclosed herein are prognostic biomarkers useful for identifying cancer-bearing subjects who are expected to have better relative survival outcomes.

Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.

The invention relates to methods of treating B-cell chronic lymphocytic leukemia, and other CD23⁺ malignancies, in patients with poor prognostic markers. The method comprises administration of an CD23 antibody, including for example, lumiliximab to a mammal that over expresses a poor prognostic marker. The method can also comprise administration of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab. Patients with poor prognostic markers include, for example, patients that overexpress ZAP70, CD38, β2-microglobulin and/or soluble CD23.

The invention belongs to the field of biological medicines and relates to an application of a GPS2 gene in preparation of drugs for prognosis, diagnosis or prevention and treatment of soft tissue tumor. The GPS2 gene is in low expression in soft-tissue sarcoma such as liposarcoma, and proliferation of the liposarcoma can be promoted by inhibiting the expression of the GPS2 gene. The expression of the GPS2 gene has obvious relevance with prognosis of the liposarcoma, which shows that the GPS2 gene can be used for clinical pathological diagnosis of patients with liposarcoma. The GPS2 gene can be used as a tumor-suppressing gene in the liposarcoma, and can be used as a possible prognostic marker and a therapeutic molecule of the liposarcoma.

The invention belongs to the technical field of glioma prognosis markers, and particularly relates to application of BACE2 as a glioma prognosis/treatment marker. According to the invention, the research results prove that high-level BACE2 expression is related to the high-level human brain glioma, the mesenchymal molecule subtype of GBM and the poor prognosis for the first time; furthermore, TGF[beta] 1 stimulates BACE2 expression by means of Smad dependent signal transduction, so as to regulate the activity of TNF-[alpha] induced NF-[kappa] B by means of a PP1/IKK pathway to promote tumorigenesis in glioma cells. The BACE2 can be used as a novel biomarker and a potential treatment target for treating human brain glioma.

There is a need to accurately monitor a cancer patient's risk status after completion of therapy due to residual disease. Herein provided are methods related to detection of cancer and cancer recurrence in a subject using detection of cell-free DNA methylation.

The invention discloses an extranodal nasal NK/T cell lymphoma prognostic marker, an application thereof, a prognostic prediction model and a construction method thereof. The prognostic marker is remarkably related to disease staging and Ki67 positive rate, and the prognostic marker is CD20; it is found for the first time that the infiltration density of CD20 positive cells in the extranodal nasalNK/T cell lymphoma tumor tissue is positively correlated with the survival time of a patient, and is negatively correlated with the disease staging of the patient; it shows that CD20 can be used as aprediction index for good prognosis of the patient; the prognostic marker CD20 can make up for the deficiency of good prognostic prediction indexes in the ENKTCL field; the construction method of theprognosis prediction model is simple; the density of CD20 positive cells in a tumor tissue slice of the patient is detected by combining an immunohistochemical method with a slice microscanning technology and the like, so that a patient prognosis prediction model is constructed; and the patient prognosis prediction model has great significance in guiding individualized treatment of clinical extranodal nasal NK/T cell lymphoma.

The invention belongs to the field of biotechnology application, and relates to a novel prediction technology for human severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2) infection, inparticular to a method for determining the content of an active urokinase receptor in a human body through enzyme-linked immunosorbent assay to serve as a prognosis biomarker of a COVID-19 patient. Bydetecting the level of an active urokinase receptor in a COVID-19 patient, an asymptomatic infector or a healthy human body, it is found that the level of active suPAR in the COVID-19 patient and theasymptomatic infector is far higher than that of active suPAR in the healthy human body, and the level of active suPAR in the asymptomatic infector is slightly higher than that of active suPAR in theCOVID-19 patient. The result obtained by the invention shows that the detection of the level of the suPAR in the body of the COVID-19 patient can be used as a prognosis biomarker of the patient, anda certain value is provided for early triage of the COVID-19 patient.

The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs and miRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided.

The invention relates to a biomarker combination used for detection of chemotherapy curative effect and/or prognosis of metastatic colorectal cancer and application thereof. The miRNA combination includes miR-135b and miR-208b. A kit includes a TaqMan probe combination of the miRNA. Serum is easy to obtain, no other tissue is needed, and the detection belongs to the non-traumatic examination, the serum miRNA reflects whole body pathological and physiological conditions, the serum miRNA as a chemotherapy curative effect and prognosis marker can improve the detection accuracy; the kit simplifies the TaqMan probe library, reduces the production cost and production time, increases the pertinence and practicability, and improves the detection sensitivity and specificity; the combination, the method and the kit can not only be used for judgment of curative effect of chemotherapy of the metastatic colorectal cancer, and also can be used for prognostic assessment of chemotherapy of the metastatic colorectal cancer.

A method for evaluating the cure level of a stroke patient comprises following steps: (1) obtaining isolated blood sample from said stroke patient; (2) determining the concentration of serum granulocyte colony-stimulating factor (G-CSF) of said blood sample; (3) comparing the relationship between said concentration of granulocyte colony-stimulating factor (G-CSF) and the stroke severity ranking of said stroke patient; wherein United State National Institute of Health Stroke Scale (NIHSS) or modified Ranking Scale (mRS) is used in said stroke severity ranking; and (4) Using said concentration of granulocyte colony-stimulating factor (G-CSF) to predict the possible cure level of said stroke patient. The invention further provides a prognosis biomarker for evaluating the cure level of a stroke patient, and a kit containing said prognosis biomarker.